Clinical Trial Update: A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804 [Phase 2]

View source ↗

Summary

Phase 2 trial update for BPS804 in adults with Osteogenesis Imperfecta types I, III, and IV has completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteogenesis Imperfecta

Drugs mentioned

• BPS804

Snippet

Sponsor: Ultragenyx Pharmaceutical Inc | Conditions: Osteogenesis Imperfecta, Type I, Osteogenesis Imperfecta Type III | Phase 2 | Status: COMPLETED | Results posted: 2022-03-02